All In MedTech

Device Trial Radar · NCT07087639

Novel Venous Cannula Trial

Safety and Effectiveness Evaluation of Novel MICS Venous Cannula

Last checked: Nov 20, 2026Latest source record: Jul 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Dec 22, 2022

Primary completion

Feb 5, 2025

Study completion Feb 5, 2025

Sponsor

Lead sponsor
Eurosets S.r.l.Not on our public-company list
Sponsor type
Industry
First posted
Jul 28, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open-label, single-arm, single-center clinical investigation designed to evaluate the safety and performance of a Novel Venous Cannula during on-pump cardiac surgery requiring transfemoral venous cannulation. The investigation aims to assess the pressure drop across the cannula during extracorporeal circulation and the incidence of serious adverse events associated with its use. A total of 42 participants will be enrolled.

Conditions

  • Cardiac Surgery
  • Heart Surgery
  • Cardiopulmonary Bypass
  • Minimally Invasive Surgical Procedures

Interventions

  • Self-expanding Venous CannulaDevice

    The intervention consists of a self-expanding venous drainage cannula made of polyurethane and reinforced with a flexible metallic mesh. It is designed for transfemoral insertion during on-pump cardiac surgery, including minimally invasive procedures. Once positioned, the cannula expands to its functional diameter to facilitate efficient blood drainage into the extracorporeal circulation system. The configuration used in this study is 680/730 mm in length, 24 Fr, 3/8" diameter. The device is sterile, single-use, and is inserted once on the day of surgery (Day 0) and removed at the end of the procedure. The cannula is used continuously during cardiopulmonary bypass for a maximum duration of 6 hours and is not reused.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effectiveness: the mean pressure drop (mm Hg) to maintain the desired flow rate (L/min) during the standard surgical procedureTime frame: During the surgical procedure (Day 0)
  2. Safety: the number of SAE with the Novel Venous Cannula during the standard surgical procedureTime frame: From Day 0 (procedure day) to 7 days post-procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Maria Cecilia Hospital

    Cotignola, RA, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.